Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Pharmaceutical Holding Ltd (NY: BHVN )

145.31 -0.40 (-0.27%)
Official Closing Price Updated: 7:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 880,622
Open 145.44
Bid (Size) 120.00 (1)
Ask (Size) 150.00 (1)
Prev. Close 145.71
Today's Range 145.10 - 145.92
52wk Range 79.01 - 151.51
Shares Outstanding 65,401,228
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Hopeful Golden Cross Forms On Biohaven Pharma Hldgs's Chart
If history is any guide, there may be good fortune ahead for shares of Biohaven Pharma Hldgs (NYSE:BHVN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish... 
Via Benzinga
Looking Into Biohaven Pharmaceutical's Return On Capital Employed
According to data from Benzinga Pro, during Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $318.85 million. Despite a 41.43% increase in earnings, the company posted a loss of $116.90... 
Via Benzinga

Performance

YTD
+4.42%
+4.42%
1 Month
+0.17%
+0.17%
3 Month
+22.01%
+22.01%
6 Month
+4.42%
+4.42%
1 Year
+47.00%
+47.00%

More News

Read More
3 Biotech Stocks to Buy Before They Boom
Via InvestorPlace
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
Via Investor's Business Daily
Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study
Via Benzinga
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN
From Kahn Swick & Foti, LLC
Via Business Wire
Recap: Biohaven Pharma Hldgs Q1 Earnings
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Via Benzinga
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
Via Benzinga
103 Biggest Movers From Yesterday
Via Benzinga
Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?
Via InvestorPlace
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; Crude Oil Down 3%
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Reverses Morning Rally as Recession Fears Swirl
Via Talk Markets
Mid-Day Market Update: U.S. Stocks Turn Lower; Biohaven Pharmaceutical Shares Jump
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'
Via Investor's Business Daily
Pfizer Acquires This Migraine Drug Maker For $11B: What Investors Need To Know
Via Benzinga
BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pfizer to Acquire Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.